Alderaan Biotechnology Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Liquidation

Alderaan Biotechnology General Information

Description

Developer of a monoclonal antibody designed to offer treatment for cancer. The company's antibodies help to deplete regulatory T cells in cancer and to boost Natural Killer cell cytotoxic activity in cancer, emerging as new immunotherapy modalities, enabling physicians to avail antibodies to use directed against immune cells in the tumor microenvironment.

Contact Information

Website
www.alderaan-biotechnology.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Rue Thénard
  • 75005 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4 Rue Thénard
  • 75005 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alderaan Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation Completed Bankruptcy: Liquidation
2. Early Stage VC (Series A) 09-Jan-2020 Completed Pre-Clinical Trials
1. Seed Round 15-Feb-2017 $1.6M $1.6M Completed Pre-Clinical Trials
To view Alderaan Biotechnology’s complete valuation and funding history, request access »

Alderaan Biotechnology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Alderaan Biotechnology’s complete cap table history, request access »

Alderaan Biotechnology Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Alderaan Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4490188-A1 Anti-cd160 transmembrane isoform antibodies Pending 09-Mar-2022
WO-2023170207-A1 Anti-cd160 transmembrane isoform antibodies Inactive 09-Mar-2022
AU-2021380966-A1 Anti-cd25 antibodies Inactive 20-Nov-2020
CA-3199006-A1 Anti-cd25 antibodies Pending 20-Nov-2020
EP-4247496-A1 Anti-cd25 antibodies Inactive 20-Nov-2020 C07K16/2866
To view Alderaan Biotechnology’s complete patent history, request access »

Alderaan Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Alderaan Biotechnology FAQs

  • When was Alderaan Biotechnology founded?

    Alderaan Biotechnology was founded in 2017.

  • Where is Alderaan Biotechnology headquartered?

    Alderaan Biotechnology is headquartered in Paris, France.

  • What is the size of Alderaan Biotechnology?

    Alderaan Biotechnology has 8 total employees.

  • What industry is Alderaan Biotechnology in?

    Alderaan Biotechnology’s primary industry is Drug Discovery.

  • Is Alderaan Biotechnology a private or public company?

    Alderaan Biotechnology is a Private company.

  • What is Alderaan Biotechnology’s current revenue?

    The current revenue for Alderaan Biotechnology is .

  • How much funding has Alderaan Biotechnology raised over time?

    Alderaan Biotechnology has raised $22.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process